3 pharma stocks to buy on dips; 3 banks that may outperform: Sanjiv Bhasin

economictimes.indiatimes.com:

Sanjiv Bhasin, Director, IIFL Securities, says “pharma is a proxy to a weak rupee and a stronger dollar becomes a very good alibi. Thirdly, the business is doing extremely well. So, Aurobindo, Lupin and Sun Pharma on declines could be a very good basket. More than that, if you cannot choose the stocks, better do a SIP in the likes of SBI or a Nippon fund. They have very good pharma funds which have got a basket of stocks. So, an ETF over there would be a very good idea if you want exposure into pharma.”

What is your view on the pharma space? The latest note by Macquarie seems to be really advocating largecaps like Sun Pharma, Dr Reddy's, etc. But given the kind of move that we have already seen, what is your outlook on pharma at the current juncture?
Pharma has been a darling of the market in the last two months after most people had written it off post Covid. But the results and the under-ownership, particularly of stocks like Auro Pharma and Lupin, which are two stocks which we have accumulated – a disclosure. We think that the largecap pharma is a very comforting space given that IT still has some of the headwinds, pharma as a proxy to a weak rupee and a stronger dollar becomes a very good alibi. Thirdly, the business is doing extremely well. So, Aurobindo, Lupin and Sun Pharma on declines could be a very good basket.

Unlock Leadership Excellence with a Range of CXO Courses

More than that, I would say that if you cannot choose the stocks, better do a SIP in the likes of SBI or a Nippon fund. They have very good pharma funds which have got a basket of stocks. So, an ETF over